206 related articles for article (PubMed ID: 29063678)
21. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma.
Abdullah C; Wang X; Becker D
Cell Cycle; 2011 Mar; 10(6):977-88. PubMed ID: 21358262
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
23. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
24. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
Wang S; Meades C; Wood G; Osnowski A; Anderson S; Yuill R; Thomas M; Mezna M; Jackson W; Midgley C; Griffiths G; Fleming I; Green S; McNae I; Wu SY; McInnes C; Zheleva D; Walkinshaw MD; Fischer PM
J Med Chem; 2004 Mar; 47(7):1662-75. PubMed ID: 15027857
[TBL] [Abstract][Full Text] [Related]
25. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Cai D; Latham VM; Zhang X; Shapiro GI
Cancer Res; 2006 Sep; 66(18):9270-80. PubMed ID: 16982772
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.
Faber AC; Chiles TC
Cell Cycle; 2007 Dec; 6(23):2982-9. PubMed ID: 18156799
[TBL] [Abstract][Full Text] [Related]
27. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
[TBL] [Abstract][Full Text] [Related]
28. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
[TBL] [Abstract][Full Text] [Related]
29. Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9.
Ayaz P; Andres D; Kwiatkowski DA; Kolbe CC; Lienau P; Siemeister G; Lücking U; Stegmann CM
ACS Chem Biol; 2016 Jun; 11(6):1710-9. PubMed ID: 27090615
[TBL] [Abstract][Full Text] [Related]
30. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
[TBL] [Abstract][Full Text] [Related]
31. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
33. A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction.
Dai XY; Zeng XX; Peng F; Han YY; Lin HJ; Xu YZ; Zhou T; Xie G; Deng Y; Mao YQ; Yu LT; Yang L; Zhao YL
Cell Physiol Biochem; 2012; 29(1-2):281-90. PubMed ID: 22415097
[TBL] [Abstract][Full Text] [Related]
34. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Wilson SC; Atrash B; Barlow C; Eccles S; Fischer PM; Hayes A; Kelland L; Jackson W; Jarman M; Mirza A; Moreno J; Nutley BP; Raynaud FI; Sheldrake P; Walton M; Westwood R; Whittaker S; Workman P; McDonald E
Bioorg Med Chem; 2011 Nov; 19(22):6949-65. PubMed ID: 21982796
[TBL] [Abstract][Full Text] [Related]
36. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma.
Shao YY; Hsu HW; Wo RR; Wang HY; Cheng AL; Hsu CH
Oncology; 2022; 100(11):602-611. PubMed ID: 36103810
[TBL] [Abstract][Full Text] [Related]
38. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
39. The anticancer activity of the substituted pyridone-annelated isoindigo (5'-Cl) involves G0/G1 cell cycle arrest and inactivation of CDKs in the promyelocytic leukemia cell line HL-60.
Saleh AM; Aljada A; El-Abadelah MM; Taha MO; Sabri SS; Zahra JA; Aziz MA
Cell Physiol Biochem; 2015; 35(5):1943-57. PubMed ID: 25870953
[TBL] [Abstract][Full Text] [Related]
40. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3β signaling.
Yu Z; Du J; Zhao Y; Gao Y; Li Y; Zhao K; Lu N
Cancer Lett; 2021 Feb; 498():31-41. PubMed ID: 33129955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]